Advanced search
Publication Cover
Seminars in Ophthalmology Volume 33, 2018 - Issue 3
Submit an article Journal homepage
1,368
Views
14
CrossRef citations to date
0
Altmetric
Original Articles

Clinical Severity and Tear Biomarkers, Eosinophil Cationic Protein and CCL23, in Chronic Allergic Conjunctival Diseases

Maki ShojiDivision of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan;Department of Ophthalmology, Diabetes Center, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
,
Jun ShojiDivision of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, JapanORCID Iconhttp://orcid.org/0000-0001-8957-3312
ORCID Icon &
Noriko InadaDivision of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0486-1230
ORCID Icon
Pages 325-330 | Received 26 Apr 2016, Accepted 08 Sep 2016, Published online: 08 Dec 2016

REFERENCES

  • Leonardi A, Castegnaro A, Valerio AL, Lazzarini D. Epidemiology of allergic sonjunctivitis: Clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol. 2015;15:482–488.
  • Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy. 2006;36:777–784.
  • Shoji J, Inada N, Sawa M. Evaluation of novel scoring system using 5-5-5 exacerbation grading scale for allergic conjunctivitis disease. Allergol Int. 2009;58:591–597.
  • Venge P, Byström M, Carlson L, et al. Eosinophil cationic protein (ECP): Molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999;29:1172–1186.
  • Montan PG, van Hage-Hamsten M. Eosinophil cationic protein in tears in allergic conjunctivitis. Br J Ophthalmol. 1996;80:556–560.
  • Shoji J, Kitazawa M, Inada N, Sawa M, Ono T, Kawamura M, et al. Efficacy of tear eosinophil cationic protein level measurement using filter paper for diagnosing allergic conjunctival disorders. Jpn J Ophthalmol. 2003;47:64–68.
  • Wakamatsu TH, Satake Y, Igarashi A, Dogru M, Ibrahim OM, Okada N, et al. IgE and eosinophil cationic protein (ECP) as markers of severity in the diagnosis of atopic keratoconjunctivitis. Br J Ophthalmol. 2012;96:581–586.
  • Leonardi A, Borghesan F, Faggian D, Secchi A, Plebani M. Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. Allergy. 1995;50:610–613.
  • Patel VP, Kreider BL, Li Y, Li H, Leung K, Salcedo T, et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of distinct classes of myeloid progenitors. J Exp Med. 1997;185:1163–1172.
  • Youn BS, Zhang SM, Broxmeyer HE, Cooper S, Antol K, Fraser M Jr, et al. Characterization of CKbeta8 and CKbeta8-1: Two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1. Blood. 1998;91:3118–3126.
  • Matsumoto K, Fukuda S, Hashimoto N, Saito H. Human eosinophils produce and release a novel chemokine, CCL23, in vitro. Int Arch Allergy Immunol. 2011;155 Suppl 1:34–39.
  • Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S, et al. Japanese guideline for allergic conjunctival diseases. Allergol Int. 2011;60:191–203.
  • Shoji J, Inada N, Sawa M. Evaluation of eotaxin-1, -2, and -3 protein production and messenger RNA expression in patients with vernal keratoconjunctivitis. Jpn J Ophthalmol. 2009;53:92–99.
  • Trocme SD, Kephart GM, Bourne WM, Buckley RJ, Gleich GJ. Eosinophil granule major basic protein deposition in corneal ulcers associated with vernal keratoconjunctivitis. Am J Ophthalmol. 1993;115:640–643.
  • Messmer EM, May CA, Stefani FH, Welge-Luessen U, Kampik A. Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis. Am J Ophthalmol. 2002;134:816–821.
  • Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008;58:2257–2267.
  • Yanaba K, Yoshizaki A, Muroi E, Ogawa F, Asano Y, Kadono T, et al. Serum CCL23 levels are increased in patients with systemic sclerosis. Arch Dermatol Res. 2011;29–34.
  • Novak H, Müller A, Harrer N, Günther C, Carballido JM, Woisetschläger M. CCL23 expression is induced by IL-4 in a STAT6-dependent fashion. J Immunol. 2007;178:4335–4341.
  • Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003;110:487–492.
  • Poposki JA, Uzzaman A, Nagarkar DR, Chustz RT, Peters AT, Suh LA, et al. Increased expression of the chemokine CCL23 in eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2011;128:73–81.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.